Roivant to Codevelop Poxel's T2D Candidate Imeglimin in Up-to-$650M Partnership

Roivant Sciences will partner with Poxel to codevelop its Phase III-ready lead candidate, the type 2 diabetes treatment imeglimin, in the U.S., Europe, and elsewhere in the world, except 13 Asian nations, through a partnership that could generate up to $650 million-plus for Poxel.The deal expands Roivant into metabolic drugs, a specialty of Poxel, and bolsters Roivant’s pipeline with a late-stage treatment that showed promising Phase IIb results in December 2014. Back then, Poxel trumpeted